Q-omics provides the consensus-scored RPL5P15 profile across patient tissues and cancer cell-line models. RPL5P15 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, RPL5P15 is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, RPL5P15 RNA expression shows 5,851 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight STAD, THCA, and GBM as cancer lineages where RPL5P15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL5P15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL5P15 survival associations across molecular data types. RPL5P15 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL5P15 RNA expression–survival associations across cancer types. High RPL5P15 expression shows unfavorable associations in STAD, LUAD, UVM and PAAD, but favorable associations in ESCA and THCA. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for RPL5P15 RNA expression.
This table summarizes RPL5P15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL5P15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL5P15 shows higher tumor expression in THCA. The THCA box plot shows higher RPL5P15 RNA expression in tumor versus normal tissue (log2 FC = +0.020, t-test p = .038).
This table shows molecular features associated with RPL5P15 in patient tissues and cancer cell lines. In patient samples, RPL5P15 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
